AbbVie Ventures and Sofinnova Partners have co-led a series A round for Enthera Pharmaceuticals, which is using stem cells to treat autoimmune disorders.
Enthera Pharmaceuticals, an Italy-based biotechnology developer focused on autoimmune conditions, today collected €28m ($32.8m) in a series A round co-led by pharmaceutical firm AbbVie’s corporate venturing arm AbbVie Ventures.
VC firm Sofinnova Partners co-led the round, which also included unnamed individuals coordinated by wealth management firm Banor SIM and by asset management firm Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners.
Founded in 2016, Enthera Pharmaceuticals is working on treatments that re-establish stem cell capabilities in the pancreas and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
